A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects with Amyotrophic Lateral Scle

Project: Research project

Project Details

Effective start/end date8/8/228/8/25


  • ICON Clinical Research, LLC (Prot#MT-1186-A02 // Prot#MT-1186-A02)
  • Mitsubishi Tanabe Pharma America, Inc. (Prot#MT-1186-A02 // Prot#MT-1186-A02)